Time filter

Source Type

Andreu-Ullrich H.,Etablissement Francais du Sang Bourgogne Franche Comte
Transfusion and Apheresis Science | Year: 2014

Extracorporeal photochemotherapy (ECP) has been applied to many T-cell mediated diseases where immunosuppressive drugs are insufficient or not tolerated. As ECP is mainly used in rare indications after failure of other therapies, controlled studies are hardly possible. In addition, the importance of the extracorporeal circuit imposes ethical doubts in organising sham ECP procedure, which explains the rarity of controlled double-blind studies.However, encouraging and even successful results have been reported in newly developed diabetes mellitus, erosive lichen planus, Crohn's disease, systemic sclerosis, nephrogenic fibrosing dermopathy, atopic dermatitis, rheumatoid arthritis, systemic lupus erythematodes, psoriasis arthritis, cutaneous mucinosis, scleromyxoedema, pemphigus vulgaris, multiple sclerosis, eosinophilic fasciitis and in the prevention of percutaneous transluminal coronary angioplasty (PTCA) restenosis.This article discusses the various levels of evidence in the above cited indications. © 2014 Elsevier Ltd. Source

Floret N.,Center Hospitalier University | Cervoni J.P.,Center Hospitalier University | Sheppard F.,Center Hospitalier University | Des Floris M.F.L.,Etablissement Francais du Sang Bourgogne Franche Comte | Duchene F.,Center Hospitalier
Journal of Hospital Infection | Year: 2013

In August 2006, the regional unit for nosocomial infection control (ARLIN) was notified of a case of symptomatic acute hepatitis B (HBV) infection in an immunosuppressed 87-year-old patient who had received a blood transfusion five months previously. Immunosuppression for the treatment of a variety of conditions is increasing. Immunosuppressed patients should be investigated for previous HBV infection and given pre-emptive therapy where indicated. We report our experience investigating a case of HBV reactivation in an immunosuppressed patient. We describe the investigation and highlight the continued need for vigilance for HBV reactivation in immunosuppressed patients who may present to a range of clinicians. © 2012 The Healthcare Infection Society. Source

Charriere K.,French Institute of Health and Medical Research | Rouleau A.,FEMTO ST Institute | Gaiffe O.,FEMTO ST Institute | Fertey J.,University of Franche Comte | And 7 more authors.
Sensors and Actuators, B: Chemical | Year: 2015

In the field of blood transfusion, there is a need to improve the bedside pre-transfusion ABO compatibility test. In France, this test is mandatory for each red cell concentrates transfusion. It is performed manually and serious transfusion accidents still occur, principally due to human errors. Therefore, an automated ABO compatibility test is required. Works concerning objective interpretation of ABO compatibility test have been reported but the proposed techniques cannot be easily translated to the patient's bedside. We propose a prototype device which demonstrates the easy use of biochip technology to perform this test: it contains a fluidic system, biochips (two to test the patient and two to test the red cell concentrates) and an optical absorbance detection module. When blood is applied to the biochips, red blood cells are trapped onto the surface if antigens and antibodies are complementary (positive chips). If they are not complementary, very little red blood cells are adsorbed (negative chips). Percentages of surface covered with red blood cells in negative biochips are 2% ± 2 (red cell concentrates) and 1% ± 1 (whole blood). This proves that the fluidic configuration leads to an optimum control of fluids flows with little retention of red blood cells in the circuitry. These percentages increase to 96% ± 3 and 82% ± 8 for red cell concentrates and whole blood respectively. This demonstrates a strong and specific immunocapture of red blood cells on positive chips. Furthermore, optical detection proves to be efficient at critical red blood cells concentrations (108 C/mL) and absorbance strongly correlates to the percentage of red blood cells captured by antibodies. © 2014 Published by Elsevier B.V. Source

Hermine O.,Paris-Sorbonne University | Lassale B.,Unite dhemovigilance | Morel P.,Etablissement Francais du Sang Bourgogne Franche Comte | Samama C.M.,University of Paris Descartes | And 5 more authors.
Transfusion Clinique et Biologique | Year: 2014

The current issues debate brings together experts around the themes of self-sufficiency (in its national and European aspects) and of needs in cellular blood products. The point of view of the manufacturer and prescribers of blood products are confronted. © 2014. Source

Sagot P.,Service de gynecologie obstetrique | Sagot P.,University of Burgundy | Mourtialon P.,Service de gynecologie obstetrique | Mourtialon P.,University of Burgundy | And 6 more authors.
European Journal of Obstetrics Gynecology and Reproductive Biology | Year: 2012

Objective: To measure the accuracy of blood transfusion (timing and number of blood units) in postpartum hemorrhage (PPH) in a perinatal network. Study design: (1) The ANONYMAT software system was used for anonymization and linkage of two large stand-alone databases, the Burgundy Perinatal Network (BPN) and the National Blood Centre (EFS) databases, which contain, respectively, clinical data from hospital discharges and information concerning any blood transfusion in France (considered as the gold standard database for identifying any transfusion). (2) Identification of prescriptions of at least one red blood cell (RBC) unit at the day of delivery (≥22 weeks) and up to 42 days, with manual reviewing of medical records in case of discordant recording. (3) Assessing the sensitivity and positive predictive value of data from the BPN database. Results: Among the 9736 women receiving at least one blood product dispensed between 01/01/2006 and 12/31/2007 and the 35,779 women who delivered, 233 women (0.65% of deliveries) received at least one RBC unit for post partum hemorrhage. In the BPN database according to the type of hospital stay in our perinatal network (delivery stay only, delivery and post-delivery stays), sensitivity and positive predictive value for RBC transfusion ranged from 61.4% (55.1-67.6) to 67.8% (61.8-73.8) and 82.2% (76.5-87.9) to 83.2% (77.8-88.5), respectively. Linkage of both BPN and EFS databases allowed accurate recording of all but one RBC transfusion. Conclusion: Our approach allowed 100% electronic recording of PPH requiring blood transfusion, making it an important sentinel event of maternal morbidity to assess the perinatal network. © 2012 Elsevier Ireland Ltd. Source

Discover hidden collaborations